1783 — Maxigen Biotech Share Price
0.000.00%
Last trade - 00:00- TWD3.76bn
- TWD3.12bn
- TWD680.65m
- 93
- 32
- 79
- 80
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.77 | ||
| Price to Tang. Book | 2.77 | ||
| Price to Free Cashflow | 14.27 | ||
| Price to Sales | 5.59 | ||
| EV to EBITDA | 15.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.07% | ||
| Return on Equity | 13.9% | ||
| Operating Margin | 26.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 457.69 | 511.98 | 604.43 | 622.12 | 680.65 | n/a | n/a | 8.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +10.18 | +32.81 | +48.58 | +19.74 | +14.28 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MAXIGEN BIOTECH INC. is a Taiwan-based company principally engaged in the manufacture and sales of biological products, the wholesale of all kinds of medical equipment, medicines, foods, masks, skin care products, as well as the manufacture and sales of chemical materials. The Company operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.
Directors
- Yung-Hsiang Lin CHM
- Jingting Chen GMG
- Qixiang Chen DGM
- Yijun Huang DGM
- Yihua You OTH
- Zhenzhen Fu DRC
- Xiuyuan Li DRC
- Shih-Ming Li IND
- Sung-Yuan Liao IND
- Zhongming Zeng IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 3rd, 1998
- Public Since
- May 18th, 2011
- No. of Employees
- 96
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 89,676,115
- Address
- No.88, Keji 1st Road, Guishan District, TAOYUAN, 333
- Web
- https://mbi-bio.com/
- Phone
- +886 33287222
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 1783
Similar to 1783
Chlitina Holding
Taiwan Stock Exchange
Farcent Enterprise Co
Taiwan Stock Exchange
Jourdeness
Taiwan Stock Exchange
KNH Enterprise Co
Taiwan Stock Exchange
Kuangli Bio Tech Holdings Co
Taiwan Stock Exchange
FAQ
What is the Maxigen Biotech share price?
As of Today at 21:57 UTC, shares in Maxigen Biotech are trading at TWD42.40. This share price information is delayed by 15 minutes.
How has the Maxigen Biotech share price performed this year?
Shares in Maxigen Biotech last closed at TWD42.40 and the price had moved by -0.24% over the past 365 days. In terms of relative price strength the Maxigen Biotech share price has outperformed the FTSE Developed Asia Pacific Index by +0.9% over the past year.
What are the analyst and broker recommendations for Maxigen Biotech?
The overall consensus recommendation for Maxigen Biotech is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Maxigen Biotech dividend yield?
Maxigen Biotech does not currently pay a dividend.
Does Maxigen Biotech pay a dividend?
Maxigen Biotech does not currently pay a dividend.
When does Maxigen Biotech next pay dividends?
Maxigen Biotech does not currently pay a dividend.
How do I buy Maxigen Biotech shares?
To buy shares in Maxigen Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Maxigen Biotech?
As of the previous close price of TWD42.40, shares in Maxigen Biotech had a market capitalisation of TWD3.76bn.
Where are Maxigen Biotech shares listed?
Here are the trading details for Maxigen Biotech:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 1783
What kind of share is Maxigen Biotech?
Based on an overall assessment of its quality, value and momentum Maxigen Biotech is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Maxigen Biotech share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Maxigen Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Maxigen Biotech. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +5.84%.
As of the last closing price of TWD42.40, shares in Maxigen Biotech were trading -6.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Maxigen Biotech PE Ratio?
The Maxigen Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD42.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Maxigen Biotech?
Maxigen Biotech's management team is headed by:
- Yung-Hsiang Lin - CHM
- Jingting Chen - GMG
- Qixiang Chen - DGM
- Yijun Huang - DGM
- Yihua You - OTH
- Zhenzhen Fu - DRC
- Xiuyuan Li - DRC
- Shih-Ming Li - IND
- Sung-Yuan Liao - IND
- Zhongming Zeng - IND